Skip to main content

Articles

R-CHOP Prevails Over Dose-Adjusted EPOCH-R as Standard of Care for Diffuse Large B-Cell Lymphoma

Novel Hypomethylating Agent Active in Patients with High-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Glasdegib, a Hedgehog Inhibitor, Nearly Doubles Survival in AML or High-Risk MDS

Multiple Myeloma, Oncology

Elotuzumab-Based Triplet Regimen Stops Progression of High-Risk Smoldering Multiple Myeloma

The Hematology Pipeline Features New Immune Therapies, and Targeted Agents

Health Plans Must Monitor the Oncology Pipeline to Apply Appropriate Coverage Criteria, Maintain Treatment Value

CAR T-Cell Therapy Succeeds in Aggressive Lymphoma

Practice Management

Induction Therapy plus Autologous Stem-Cell Transplantation Still Cost-Effective for Newly Diagnosed Multiple Myeloma

Obinutuzumab Prolongs Survival in Follicular Lymphoma

Letters to the Editor

Misunderstanding of Findings Related to a Recent Article

Page 97 of 244
Results 961 - 970 of 2434